Low-energy, double-pass 1450-nm diode laser provides an efficient and well endured treatment option for acne scars, according to study data published in Dermatologic Therapy.

The multi-center, cross-sectional study enrolled a total of 48 patients (30 women, mean age, 24.32 ± 8.64 years, and skin types II-V) with facial acne scars from April 2018 to April 2019. Low-energy, double-pass 1450-nm diode laser was used in the treatment areas in all patients at 4-week intervals for a total of 5 treatments. Evaluations of the lesions were performed clinically and with photographs before treatment, during treatment, 4 weeks post treatment, and 3rd month post final treatment and during follow-up visit. Improvement levels were assessed based on the following series: unaltered (without change), slight improvement (1%-29%), moderate improvement (30%-69%), and marked improvement (70%-100%). Patients were also asked to note any adverse events as well as their level of satisfaction (no satisfaction, slight satisfaction, satisfied, or very satisfied.)

The results revealed moderate to marked improvement in 79.2% of the patients, of whom 31.2% demonstrated moderate improvement and 48% presented marked improvement. At the end of 3rd month follow-up, 92.9% of the patients demonstrated moderate to marked improvement (>30%). In all, 8.3% demonstrated no alteration and no worsening of scars was seen in any patient. Overall, 83.3% of the study population was either satisfied or very satisfied. They also noted that low postinflammatory hyperpigmentation was seen in patients with darker skin.

Related Articles

The investigators conclude that the “nonablative 1450-nm diode laser may be considered as a better alternative over ablative lasers considering the lesser downtime and fewer complications caused by it.”


Continue Reading

Follow @DermAdvisor

Reference

Rathod D, Foroughi A, Mekokishvili L, , et al. A cross-sectional, multi-center study on treatment of facial acne scars with low-energy double-pass 1450-nm diode laser (published online March 24, 2020). Dermatol Ther. doi: 10.1111/dth.13326